Top Viscosupplementation Solution Providers in 2025
19 May, 2025

The Global Viscosupplementation Market is anticipated to expand at a compound annual growth rate (CAGR) of 9.02% from 2025 to 2033, from US$ 4.66 billion in 2024 to US$ 10.16 billion by2033. Due to an increase in osteoarthritis patients and a growing need for minimally invasive therapies, the market for viscosupplementation is expanding significantly. Hyaluronic acid is injected into joints as part of this therapy to reduce discomfort and increase range of motion, especially in the knee. Elderly people who are looking for alternatives to surgery for joint pain prefer it. Commonly utilized systems include single, dual, and multiple injections; single-injection treatments are becoming more and more popular due to their ease. The market is expanding because to better formulations, increased knowledge of osteoarthritis treatment alternatives, and technological improvements. Even while the therapy has advantages like reduced pain and better joint function, there are still issues including inconsistent patient reactions and legal restrictions. In general, viscosupplementation is still the recommended course of action for orthopedic treatment. Similarly, at a compound annual growth rate (CAGR) of 10.1% from 2025 to 2033, the Asia-Pacific Viscosupplementation Market is projected to grow from US$ 1.60 billion in 2024 to US$ 3.80 billion by 2033.

Companies that sell viscosupplements are experts in creating hyaluronic acid-based treatments to reduce joint discomfort, especially in those with osteoarthritis. They concentrate on developing injectable therapies that improve mobility and lessen pain by restoring joint lubricant. These companies make significant investments in R&D to improve patient outcomes and product efficacy. Systems for single, dual, and multiple injections that are suited to different patient requirements are among their offers. These businesses, which place a high priority on innovation, seek to improve the quality of life for people with joint degeneration by offering less invasive surgical options.

Discover key trends, growth opportunities, and major challenges shaping the Viscosupplementation Industry in Renub Research’s latest in-depth market report. Download your free sample now

Companies Offering Advanced Viscosupplementation Therapies

Anika Therapeutics Inc

Establishment: 1992

Headquarters: United States of America

Website: www.anika.com

Revenue: $166.7M in 2023

Therapeutic treatments for traumatic situations and degenerative orthopedic illnesses are developed, produced, and marketed by Anika Therapeutics Inc. (Anika). It provides solutions for veterinary, surgical, ophthalmic, cutaneous, and orthobiologic applications. Visco-supplementation for humans and animals, joint implants, instrumentation, joint replacement solutions, orthopedic and regenerative surgical treatments, bone repair therapy, improved wound care, and ophthalmic products are some of its main offerings. The firm uses a technique called HYAFF, which is a solid version of hyaluronic acid (HA), to make its products. Bedford, Massachusetts is home to Anika's manufacturing and research facilities. Distributors throughout Latin America, Canada, Europe, the Middle East, and Asia are how the corporation sells its goods. The US city of Bedford, Massachusetts, is home to Anika's headquarters.

Zimmer Biomet

Establishment: 1927

Headquarters: United States of America

Website: www.zimmerbiomet.com/en

Revenue: $7.7B in 2023

The medical device business Zimmer Biomet Holdings Inc. (Zimmer Biomet) specializes in musculoskeletal treatment. Biologics, sports medicine, trauma, extremities, and orthopedic reconstructive products are all designed, produced, and marketed by the company. It also produces a suite of integrated digital and robotic technologies, office-based technologies, craniomaxillofacial and thoracic products, and related surgical products. Patients with diseases or injuries of the bones, joints, and supporting soft tissues can benefit from its products and remedies. In addition to hospitals, healthcare dealers, healthcare buying organizations, orthopedic surgeons, neurosurgeons, and other experts, Zimmer Biomet also supplies stocking distributors. Direct sales channels and distributors across the Americas, Europe, Asia-Pacific, the Middle East, and Africa are how the corporation advertises its goods. The US headquarters of Zimmer Biomet are located in Warsaw, Indiana.

Smith & Nephew PLC

Establishment: 1856

Headquarters: United Kingdom

Website: www.cinfin.com

Revenue: $5.8B in 2023

Smith & Nephew Plc (Smith & Nephew) is a medical technology firm that creates, produces, and sells medical devices for advanced wound care, sports medicine, orthopedic reconstruction and trauma, and ENT. Advanced goods and tools for repairing or removing soft tissue, hip, knee, and shoulder replacement systems, robotics-assisted and digital enabling solutions, wound dressings, advanced wound bio-actives, and advanced wound devices are among its offerings. Under the trademarks Oasis, Opsite, Pico, Primapore, Profore, and Renasys, among others, the firm sells its products to surgeons, nurses and nurse specialists, doctors and general practitioners, and purchasing professionals in hospitals and healthcare insurers. The firm sells its goods across the Middle East, Africa, Asia Pacific, Europe, and the Americas. In the United Kingdom, Smith & Nephew's headquarters are located in Watford, Hertfordshire.

F.Hoffmann-La Roche Ltd

Establishment: 1896

Headquarters: Switzerland

Website: www.roche.com

The biotechnology business F. Hoffmann-La Roche Ltd. (Roche) offers in-vitro diagnostics as well as revolutionary, cutting-edge treatments for a number of important disease areas. It offers medications to treat a variety of illnesses, including cancer, autoimmune diseases, disorders of the central nervous system, ophthalmological disorders, infectious diseases, and respiratory disorders. Additionally, the firm provides diabetes management systems, tissue-based cancer diagnostics, and in-vitro diagnostics. Roche carries out research to find new ways to diagnose, cure, and prevent illnesses. Hospitals, medical experts, commercial labs, researchers, and pharmacists are among the clients the firm serves with its goods and services. The headquarters of Roche are located in Basel, Switzerland.

Sanofi

Establishment: 1973

Headquarters: France

Website: www.sanofi.com

Revenue: $47.9B in 2023

The healthcare business Sanofi is involved in the research, development, production, and distribution of a variety of medications and vaccines. Its product line includes vaccinations for humans to protect against a variety of bacterial and viral illnesses, medications to treat cancer, uncommon disorders, and multiple sclerosis, and other items. In addition, the firm sells consumer health goods for women's health, allergies, cough, cold, flu, and sinuses, pain, and vitamins, minerals, and supplements. Sanofi's research and development activities are concentrated on developing a combination medication to boost treatment efficacy and on developing novel biologics formulations to create precision medications. It operates in the Middle East, Asia-Pacific, Africa, the Americas, and Europe. The headquarters of Sanofi are located in Paris, France's Ile-de-France.

Chugai Pharmaceutical Co

Establishment: 1925

Headquarters: Japan

Website: www.chugai-pharm.co.jp

Revenue: $8.1B in 2023

A division of F. Hoffmann-La Roche Ltd., Chugai Pharmaceutical Co. Ltd. (Chugai) is focused on medicine production and biotechnological research. Pharmaceutical items are manufactured, marketed, exported, and imported by the corporation in Japan and other nations. The business provides products to treat a range of medical conditions, such as cancer, ailments of the bones and joints, kidneys, immunological systems, and infectious diseases, among others. Additionally, it provides medications to support liver, kidney, and other organ transplants. The business sells its pharmaceutical goods in international markets such as North America, Europe, and Asia through its network of subsidiaries. Tokyo, Japan's Chuo-ku is home to Chugai's headquarters.

Lifecore Biomedical

Establishment: 1965

Headquarters: United States

Website: http://www.lifecore.com

A contract development and manufacturing organization (CDMO) known for its proficiency in intricate injectable treatments is Lifecore Biomedical. The firm has been a world leader in pharmaceutical-grade sodium hyaluronate (NaHy) for almost 40 years, and it specializes in creating and producing very viscous solutions. From early formulation to commercialization, Lifecore assists pharmaceutical and biotech partners by providing customized solutions for aseptically filled and challenging-to-formulate medicinal products. Lifecore, which is well-known for its cutting-edge skills and comprehensive assistance, is essential to bringing difficult treatments to market effectively and securely by meeting important demands throughout the drug research and manufacturing lifecycle.

LG Life Sciences Ltd.

Establishment: 2002

Headquarters: South Korea

Website: www.lgchem.com

Revenue: $35.9B in 2023

The chemical firm LG Chem Ltd. (LG Chem) produces and sells innovative materials, petrochemicals, and life science goods. Acrylonitrile butadiene styrene, acrylate, bisphenol, OLED materials, and battery materials are among the company's main products. The well-known brands Synovian, Eutropin, and Zemiglo are connected to LG Chem. Numerous sectors, including automotive, household appliances, packaging, textiles, agricultural, and industrial items, use its products. Among other industries, LG Chem's products are used in autos, household appliances, packaging, textiles, agriculture, and industrial goods. Among other places, the business operates in China, India, Germany, the United States, Vietnam, Brazil, Taiwan, Hong Kong, and Poland. The headquarters of LG Chem are located in Seoul, South Korea.